Abstract
Little is known of the eastern North American population of Barrow's Goldeneyes (Bucephala islandica), which was recently listed as “of special concern” in Canada. In 1998 and 1999, we marked 18 adult males wintering along the St. Lawrence River, Québec, with satellite transmitters to document their breeding, molting, and wintering distribution and phenology, and to describe timing and routes of their spring, molt, and fall migrations. Thirteen males moved inland from the St. Lawrence River to breed; the spring migration averaged 5.9 days, and birds arrived on breeding areas on average 9 May. All breeding areas were inland, on the north shore of the St. Lawrence River estuary and gulf. Breeding areas averaged 64.8 km from the St. Lawrence corridor. Males stayed on their respective breeding area a mean of 34.5 days, and left on average 11 June. Twelve males were tracked to their molting areas, one of which stayed on its wintering area until 5 June and flew directly to its molting area. Their molt migration averaged 18.6 days, and the mean arrival date on molting areas was 30 June. All molting areas were located north and averaged 986 km from breeding areas. Four males molted in Hudson Bay, four in Ungava Bay, two in northern Labrador, one on Baffin Island, and one inland, near the Québec–Labrador border. The mean length of stay on the molting areas was 105.3 days, and the mean date of departure from molting areas was 4 October. All goldeneyes for which the radio still functioned during fall migration returned to winter in the St. Lawrence River estuary, on average 6 November. Our results refute the idea that the main breeding area of the eastern North American population of Barrow's Goldeneyes is located in northern Québec and Labrador and rather indicate that it is in the boreal forest just north of the St. Lawrence River estuary and gulf. They also indicate that Barrow's Goldeneye males undertake a genuine molt migration, and highlight the importance of molting areas because birds stayed there approximately four months each year.
P035 Ozanimod for Moderate-to-Severe Ulcerative Colitis: North American Population Results During Induction and Maintenance in the Phase 3 True North Study
